SEC Form 4 · accession 0001179110-18-001888
Kala Pharmaceuticals, Inc. · KALA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michele LaRussa
Officer — Sr. VP, Regulatory and Quality
Period of report
Feb 7, 2018
Accepted (ET)
Feb 9, 2018 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479419
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.86 | Feb 7, 2018 | A | 8,000 | A | — | Feb 6, 2028 | Common Stock | 8,000 | 8,000 | D |
Explanation of responses
- F1This option was granted on February 7, 2018 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.